via University of Manchester
Scientists have discovered a new route to produce complex antibiotics exploiting gene editing to re-programme pathways to future medicines urgently required to combat antimicrobial resistance, treat neglected diseases and tackle future pandemics.
Researchers from The University of Manchester have discovered a new way of manipulating key assembly line enzymes in bacteria which could pave the way for a new generation of antibiotic treatments.
New research published today in Nature Communications, describes how CRISPR-Cas9 gene editing can be used to create new nonribosomal peptide synthetase (NRPS) enzymes that deliver clinically important antibiotics. NRPS enzymes are prolific producers of natural antibiotics such as penicillin. However, up until now, manipulating these complex enzymes to produce new and more effective antibiotics has been a major challenge.
The UK government suggest antimicrobial resistance (AMR) infections are estimated to cause 700,000 deaths each year globally and are predicted to rise to 10 million, costing the global economy $100 trillion, by 2050. AMR also threatens many of the UN’s Sustainable Development Goals (SDGs), with an extra 28 million people that could be forced into extreme poverty by 2050 unless AMR is contained.
The Manchester team says the gene editing process could be used to produce improved antibiotics and possibly lead to the development of new treatments helping in the fight against drug-resistant pathogens and illnesses in the future. Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology (MIB), UK, explains: “The emergence of antibiotic-resistant pathogens is one of the biggest threats we face today.”
“The gene editing approach we developed is a very efficient and rapid way to engineer complex assembly line enzymes that can produce new antibiotic structures with potentially improved properties.”
The emergence of antibiotic-resistant pathogens is one of the biggest threats we face today. The gene editing approach we developed is a very efficient and rapid way to engineer complex assembly line enzymes that can produce new antibiotic structures with potentially improved properties.
Professor Jason Micklefield
Microorganisms in our environment, such as soil dwelling bacteria, have evolved nonribosomal peptide synthetase enzymes (NRPS) that assemble building blocks called amino acids into peptide products which often have very potent antibiotic activity. Many of the most therapeutically important antibiotics, used in the clinic today, are derived from these NRPS enzymes (e.g. penicillin, vancomycin and daptomycin).
Unfortunately, deadly pathogens are emerging which are resistant to all of these existing antibiotic drugs. One solution could be to create new antibiotics with improved properties that can evade the resistance mechanisms of the pathogens. However, the nonribosomal peptide antibiotics are very complex structures which are difficult and expensive to produce by normal chemical methods. To address this, the Manchester team use gene editing to engineer the NRPS enzymes, swapping domains that recognise different amino acid building blocks, leading to new assembly lines that can deliver new peptide products.
Micklefield added: “We are now able to use gene editing to introduce targeted changes to complex NRPS enzymes, enabling alternative amino acids precursors to be incorporated into the peptide structures. We are optimistic that our new approach could lead to new ways of making improved antibiotics which are urgently needed to combat emerging drug-resistant pathogens.”
Original Article: Manchester scientists produce new antibiotics by gene editing
More from: University of Manchester
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New antibiotics development
- EVŌQ Bio Completes Successful Pre-Investigational New Drug Meeting With FDA for Development of Inhaled Therapeutic to Treat Pulmonary Infections
EVŌQ Bio, a wholly-owned subsidiary of EVŌQ Nano, today announced the successful completion of a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) ...
- Machine learning model uncovers new drug design opportunities
Pathogens are nothing if not adaptable, and their ability to protect themselves against antibiotics increasingly poses a public health concern. A research team led by Los Alamos National Laboratory ...
- Researchers find new approach for antibiotic development
The opportunistic bacterial pathogen Pseudomonas aeruginosa is dangerous due to its resistance to multiple antibiotics. A research team from Heinrich Heine University Düsseldorf (HHU) and Jülich ...
- Report urges G7 countries to commit to incentives for antibiotic development
The report from the Global Coalition on Aging calls on G7 countries to contribute their 'fair share' to incentive structures to develop new antibiotics.
- A mother’s loss launches a global effort to fight antibiotic resistance
Diary Of A Dying Girl” excerpts Mallory Smith's own writings, which chronicle her 13-year battle against an antibiotic-resistant lung infection.
Go deeper with Google Headlines on:
New antibiotics development
[google_news title=”” keyword=”new antibiotics development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic treatments
- EVŌQ Bio Completes Successful Pre-Investigational New Drug Meeting With FDA for Development of Inhaled Therapeutic to Treat Pulmonary Infections
EVŌQ Bio, a wholly-owned subsidiary of EVŌQ Nano, today announced the successful completion of a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) ...
- Study reveals unintended consequences of antibiotic choice in sepsis treatment Treatment With ...
They found marked differences: treatment with piperacillin-tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure. "These ...
- Researchers find new approach for antibiotic development
The opportunistic bacterial pathogen Pseudomonas aeruginosa is dangerous due to its resistance to multiple antibiotics. A research team from Heinrich Heine University Düsseldorf (HHU) and Jülich ...
- Syphilis up 80% in Hamilton County, highlighting treatment barriers across Ohio
With syphilis peaking in Hamilton County and across the country, doctors point to a lack of accessible testing in the state as a barrier to treatment.
- Antibiotic for Treating Sepsis Linked to Increased Mortality
"A 2% to 5% mortality difference may not initially sound like much, but given how common and deadly sepsis is, the routine use of anti-anaerobic antibiotics in sepsis may lead to thousands of deaths ...
Go deeper with Google Headlines on:
Antibiotic treatments
[google_news title=”” keyword=”antibiotic treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]